Literature DB >> 3900205

Functional analysis of mononuclear cells infiltrating into tumors. II. Differential ability of mononuclear cells obtained from various tissues to produce helper factors that are involved in the generation of cytotoxic cells.

T Uede, H Kohda, Y Ibayashi, H Osawa, T Diamantstein, K Kikuchi.   

Abstract

The requirement of CGF in the generation of cytotoxic cells against syngeneic tumor cells (T-9) and in the rejection of transplanted T-9 cells has been investigated. Spleen cells obtained from sensitized rats showed strong cytotoxicity against 51Cr-labeled T-9 cells upon incubation with CGF for 48 hr. Human recombinant IL 2 and rat IFN failed to generate cytotoxic cells from spleen cells of sensitized rats. CGF are produced by spleen cells upon inoculation of T-9 cells into sensitized rats as a host in vivo immune response. Production of CGF preceded the appearance of cytotoxic cells in regional lymph node and tumor tissues. In those rats, inoculated tumor cells were eventually rejected. In contrast, spleen cells failed to produce CGF upon inoculation of T-9 cells in unsensitized rats. Cytotoxic cells were not detected in unsensitized rats, and inoculated tumor grew in those rats. Thus, CGF is likely to be involved in the generation of cytotoxic cells and in the rejection of inoculated syngeneic tumor cells. A Mono Q anion-exchange column with an FPLC system allowed the chromatographic separation of CGF from IL 1, IL 2, IL 3, and CSF.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900205

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Flow cytometric and functional analysis of mononuclear cells infiltrating the liver in experimental autoimmune hepatitis.

Authors:  H Kohda; C Sekiya; M Kanai; Y Yoshida; T Uede; K Kikuchi; M Namiki
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Immunohistological analysis of tumour infiltrating lymphocytes in seminoma using monoclonal antibodies.

Authors:  T Nakanoma; K Nakamura; N Deguchi; J Fujimoto; H Tazaki; J Hata
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

4.  Inhibition of interleukin-1 beta release from cultured human peripheral blood mononuclear cells by prednisolone.

Authors:  A Uehara; H Kohda; C Sekiya; Y Takasugi; M Namiki
Journal:  Experientia       Date:  1989-02-15

5.  Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma.

Authors:  H Kohda; C Sekiya; Y Torimoto; M Mizuno; Y Fujimoto; T Tanaka; A Matsumoto; Y Murazumi; M Ohhira; C Hasebe
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

6.  The heterogeneity of target recognition by lymphokine-activated killer precursor cells.

Authors:  Y Ibayashi; J D Gray; S H Golub; M Daibo; T Yamaki; T Kawahara; T Kubota; K Hashi
Journal:  Jpn J Cancer Res       Date:  1990-09

7.  Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients.

Authors:  Y Inoue; N Shijubo; T Uede
Journal:  Jpn J Cancer Res       Date:  1990-10

8.  Functional analysis of mononuclear cells infiltrating into tumors: establishment of a new system to obtain functionally active tumor-infiltrating cells.

Authors:  N Shijubo; T Uede; N Nomura; K Kikuchi
Journal:  Jpn J Cancer Res       Date:  1990-01

9.  Two distinct mechanisms involved in the infiltration of lymphocytes into tumors.

Authors:  N Shijubo; T Uede; T Takami; Y Torimoto; D Lupin; S Min; K Kikuchi
Journal:  Jpn J Cancer Res       Date:  1988-10

10.  Immunotherapy of solid tumor by intratumoral infusion of lymphokine-activated killer cells.

Authors:  T Yamaki; Y Ibayashi; T Nakamura; N Shijubo; M Daibo; T Kawahara; K Hashi
Journal:  Jpn J Cancer Res       Date:  1988-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.